FADS2 and cancer: Now, we demonstrated that treatment of PCC-cancer-derived cell lines with a polyamine analogue inhibitor DENSPM results in a broad downregulation of gene expression associated with fatty acid synthesis and processing, including FASN, SCD1, FADS2, and SREBPs.